GSK_Annual_Report_2021

Notes to the Consolidated Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 223 ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 (b) Payments made during the year under the long-term incentive plan (Refer Note below): Mr. A. Vaidheesh - 3,26.95 Ms. P. Thakur 27.89 35.36 Mr. R. Krishnaswamy 53.24 28.90 Mr. S. Dheri 26.48 31.82 Mr. A. Iyer 89.16 11.48 Mr. B. Kotak 43.36 - Note: Amounts are not comparable as they pertain to part of the year and/ or are recorded on cash payment basis. Note 52 : Share-based payment arrangements Restricted Share Awards (RSAs) Certain employees of the Group are entitled to receive cash settled stock based awards (‘awards’) pursuant to employee share schemes (‘scheme’) administered by GlaxoSmithKline Plc. (‘Plc’). Under this plan, certain employees are granted cash settled RSAs at no cost, which entitle them to receive cash equivalent to the stock price of the Plc’s shares listed at London stock exchange after two and a half to three year vesting period during which the employee has to remain in continuous employment with the Group. These RSA’s do not give any voting rights or the right to accrue dividends. The fair value of these awards is determined based on the closing share price on the day of grant, after deducting the expected future dividend yield of 5% (Previous Year 4.2%) over the duration of the award. Reconciliation of RSAs Number of RSA As at April 1, 2019 139,839 Granted 122,201 Exercised * (43,148) Cancelled** (50,616) As at March 31, 2020 168,276 Granted 95,703 Exercised * (61,387) Cancelled** (37,408) As at March 31, 2021 165,184 *The weighted average share price at the date of exercise of the awards exercised during the year ended March 31, 2021 was GBP 12.88 (March 31, 2020 GBP 15.15) ** Also includes for employees transferred